Loading...
ROCO
6649
Market cap68mUSD
Nov 13, Last price  
51.20TWD
Name

Taiwan Biomaterial Co Ltd

Chart & Performance

D1W1MN
ROCO:6649 chart
P/E
P/S
22.27
EPS
Div Yield, %
Shrs. gr., 5y
5.05%
Rev. gr., 5y
42.31%
Revenues
97m
+32.59%
2,059,0001,879,0001,004,00016,543,00018,075,00041,674,000127,306,00072,838,00096,574,000
Net income
-2m
L-82.90%
-32,601,000-49,629,000-60,541,000-71,299,000-55,366,000-47,442,00033,755,000-10,130,000-1,732,000
CFO
18m
P
-32,054,000-42,268,000-60,720,000-65,438,999-44,398,000-32,009,00035,025,000-10,163,00018,427,000
Dividend
Aug 09, 20230.2 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Taiwan Biomaterial Co., Ltd. engages in the development and sale of medical devices in Taiwan. The company provides Foamagen, a foamy dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and the nickel-titanium guidewire for guiding cerebral vascular surgery; and tissue repair and regeneration products for the treatment of early osteoarthritis. Taiwan Biomaterial Co., Ltd. Was founded in 2010 and is based in Zhubei, Taiwan.
IPO date
Aug 29, 2017
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT